Nelfinavir inhibits maturation and export of herpes simplex virus 1

Journal of Virology

Volumn 88, Issue 10, 2014, Pages 5455-5461

  Kalu, Nene N ^a,b   Desai, Prashant J ^a   Shirley, Courtney M ^a   Gibson, Wade ^b   Dennis, Phillip A ^a,b   Ambinder, Richard F ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; G 2536; GANCICLOVIR; GLYCOPROTEIN; NELFINAVIR; UNCLASSIFIED DRUG; Z 0013;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL LYSATE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DRUG INHIBITION; HERPES SIMPLEX VIRUS 1; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; LIGHT SCATTERING; NONHUMAN; NUCLEIC ACID SYNTHESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROCESSING; PROTEIN TRANSPORT; VIRION; VIROGENESIS; VIRUS CAPSID; VIRUS ENVELOPE; VIRUS PARTICLE; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; HERPESVIRUS 1, HUMAN; HUMANS; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON; NELFINAVIR; ULTRACENTRIFUGATION; VIRAL PLAQUE ASSAY; VIRUS ASSEMBLY; VIRUS RELEASE;

EID: 84899067359     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03790-13     Document Type: Article

References (42)

1. Roizman B, Knipe D, Whitley R. 2007. Herpes simplex viruses, p 2501- 2602. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Gibson W, Roizman B. 1972. Proteins specified by herpes simplex virus. 8. Characterization and composition of multiple capsid forms of subtypes 1 and 2. J. Virol. 10:1044-1052.
3. Cardone G, Heymann JB, Cheng N, Trus BL, Steven AC. 2012. Procapsid assembly, maturation, nuclear exit: dynamic steps in the production of infectious herpesvirions. Adv. Exp. Med. Biol. 726:423-439. http://dx.doi.org/10.1007/978-1-4614-0980-9_19.
4. Liu F, Roizman B. 1993. Characterization of the protease and other products of amino-terminus-proximal cleavage of the herpes simplex virus 1 UL26 protein. J. Virol. 67:1300-1309.
5. Matusick-Kumar L, McCann PJ, 3rd, Robertson BJ, Newcomb WW, Brown JC, Gao M. 1995. Release of the catalytic domain N(o) from the herpes simplex virus type 1 protease is required for viral growth. J. Virol. 69:7113-7121.
6. Preston VG, Al-Kobaisi MF, McDougall IM, Rixon FJ. 1994. The herpes simplex virus gene UL26 proteinase in the presence of the UL26.5 gene product promotes the formation of scaffold like particles. J. Gen. Virol. 75:2355-2366. http://dx.doi.org/10.1099/0022-1317-75-9-2355.
7. Welch AR, Woods AS, McNally LM, Cotter RJ, Gibson W. 1991. A herpesvirus maturational protease, assemblin: identification of its gene, putative active site domain, and cleavage site. Proc. Natl. Acad. Sci. U. S. A. 88:10792-10796. http://dx.doi.org/10.1073/pnas.88.23.10792.
8. Whitley RJ, Kimberlin DW, Roizman B. 1998. Herpes simplex viruses. Clin. Infect. Dis. 26:541-553. http://dx.doi.org/10.1086/514600.
9. Turcotte S, Letellier J, Lippe R. 2005. Herpes simplex virus type 1 capsids transit by the trans-Golgi network, where viral glycoproteins accumulate independently of capsid egress. J. Virol. 79:8847-8860. http://dx.doi.org/10.1128/JVI.79.14.8847-8860.2005.
10. Chouljenko DV, Kim IJ, Chouljenko VN, Subramanian R, Walker JD, Kousoulas KG. 2012. Functional hierarchy of herpes simplex virus 1 viral glycoproteins in cytoplasmic virion envelopment and egress. J. Virol. 86: 4262-4270. http://dx.doi.org/10.1128/JVI.06766-11.
11. Farnsworth A, Goldsmith K, Johnson DC. 2003. Herpes simplex virus glycoproteins gD and gE/gI serve essential but redundant functions during acquisition of the virion envelope in the cytoplasm. J. Virol. 77:8481- 8494. http://dx.doi.org/10.1128/JVI.77.15.8481-8494.2003.
12. Farnsworth A, Johnson DC. 2006. Herpes simplex virus gE/gI must accumulate in the trans-Golgi network at early times and then redistribute to cell junctions to promote cell-cell spread. J. Virol. 80:3167-3179. http://dx.doi.org/10.1128/JVI.80.7.3167-3179.2006.
13. Farnsworth A, Wisner TW, Webb M, Roller R, Cohen G, Eisenberg R, Johnson DC. 2007. Herpes simplex virus glycoproteins gB and gH function in fusion between the virion envelope and the outer nuclear membrane. Proc. Natl. Acad. Sci. U. S. A. 104:10187-10192. http://dx.doi.org/10.1073/pnas.0703790104.
14. Mettenleiter TC, Klupp BG, Granzow H. 2009. Herpesvirus assembly: an update. Virus Res. 143:222-234. http://dx.doi.org/10.1016/j.virusres.2009.03.018.
15. Gaudreau A, Hill E, Balfour HH, Jr, Erice A, Boivin G. 1998. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J. Infect. Dis. 178:297-303. http://dx.doi.org/10.1086/515626.
16. Nichols WG, Boeckh M, Carter RA, Wald A, Corey L. 2003. Transferred herpes simplex virus immunity after stem-cell transplantation: clinical implications. J. Infect. Dis. 187:801- 808. http://dx.doi.org/10.1086/367894.
17. Gantt S, Carlsson J, Ikoma M, Gachelet E, Gray M, Geballe AP, Corey L, Casper C, Lagunoff M, Vieira J. 2011. The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro. Antimicrob. Agents Chemother. 55:2696-2703. http://dx.doi.org/10.1128/AAC.01295-10.
18. Piret J, Boivin G. 2011. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob. Agents Chemother. 55:459-472. http://dx.doi.org/10.1128/AAC.00615-10.
19. Desai P, Sexton GL, Huang E, Person S. 2008. Localization of herpes simplex virus type 1 UL37 in the Golgi complex requires UL36 but not capsid structures. J. Virol. 82:11354-11361. http://dx.doi.org/10.1128/JVI.00956-08.
20. Coen DM, Kosz-Vnenchak M, Jacobson JG, Leib DA, Bogard CL, Schaffer PA, Tyler KL, Knipe DM. 1989. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc. Natl. Acad. Sci. U. S. A. 86:4736-4740. http://dx.doi.org/10.1073/pnas.86.12.4736.
21. Desai P, DeLuca NA, Person S. 1998. Herpes simplex virus type 1 VP26 is not essential for replication in cell culture but influences production of infectious virus in the nervous system of infected mice. Virology 247:115- 124. http://dx.doi.org/10.1006/viro.1998.9230.
22. Schmidtke M, Schnittler U, Jahn B, Dahse H, Stelzner A. 2001. A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1. J. Virol. Methods 95:133- 143. http://dx.doi.org/10.1016/S0166-0934(01)00305-6.
23. Desai P. 2000. A null mutation in the UL36 gene of herpes simplex virus type 1 results in the accumulation of unenveloped DNA-filled capsids in the cytoplasm of infected cells. J. Virol. 74:11608-11618. http://dx.doi.org/10.1128/JVI.74.24.11608-11618.2000.
24. Walters JN, Sexton GL, McCaffery JM, Desai P. 2003. Mutation of single hydrophobic residue I27, L35, F39, L58, L65, L67, or L71 in theNterminus of VP5 abolishes interaction with the scaffold protein and prevents closure of herpes simplex virus type 1 capsid shells. J. Virol. 77:4043-4059. http://dx.doi.org/10.1128/JVI.77.7.4043-4059.2003.
25. Desai P, Person S. 1998. Incorporation of the green fluorescent protein into the herpes simplex virus type 1 capsid. J. Virol. 72:7563-7568.
26. Kim HS, Huang E, Desai J, Sole M, Pryce EN, Okoye ME, Person S, Desai PJ. 2011. A domain in the herpes simplex virus 1 triplex protein VP23 is essential for closure of capsid shells into icosahedral structures. J. Virol. 85:12698-12707. http://dx.doi.org/10.1128/JVI.05791-11.
27. Klupp BG, Granzow H, Mettenleiter TC. 2011. Nuclear envelope breakdown can substitute for primary envelopment-mediated nuclear egress of herpesviruses. J. Virol. 85:8285-8292. http://dx.doi.org/10.1128/JVI.00741-11.
28. Desai P, Sexton G, McCaffery J, Person S. 2001. A null mutation in the gene encoding the UL37 polypeptide of herpes simplex virus type 1 abrogates virus maturation. J. Virol. 75:10259-10271. http://dx.doi.org/10.1128/JVI.75.21.10259-10271.2001.
29. Fuchs W, Klupp BG, Granzow H, Mettenleiter TC. 2004. Essential function of the pseudorabies virus UL36 gene product is independent of its interaction with the UL37 protein. J. Virol. 78:11879-11889. http://dx.doi.org/10.1128/JVI.78.21.11879-11889.2004.
30. Johnson DC, Wisner TW, Wright CC. 2011. Herpes simplex virus glycoproteins gB and gD function in a redundant fashion to promote secondary envelopment. J. Virol. 85:4910-4926. http://dx.doi.org/10.1128/JVI.00011-11.
31. Roberts AP, Abaitua F, O'Hare P, McNab D, Rixon FJ, Pasdeloup D. 2009. Differing roles of inner tegument proteins pUL36 and pUL37 during entry of herpes simplex virus type 1. J. Virol. 83:105-116. http://dx.doi.org/10.1128/JVI.01032-08.
32. Mossman KL, Sherburne R, Lavery C, Duncan J, Smiley JR. 2000. Evidence that herpes simplex virus VP16 is required for viral egress downstream of the initial envelopment event. J. Virol. 74:6287-6299. http://dx.doi.org/10.1128/JVI.74.14.6287-6299.2000.
33. Bernstein WB, Dennis PA. 2008. Repositioning HIV protease inhibitors as cancer therapeutics. Curr. Opin. HIV AIDS 3:666-675. http://dx.doi.org/10.1097/COH.0b013e328313915d.
34. Gills JJ, Lopiccolo J, Dennis PA. 2008. Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy. Autophagy 4:107- 109. PMID:18000394.
35. Guan M, Fousek K, Chow WA. 2012. Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer. FEBS J. 279:2399-2411. http://dx.doi.org/10.1111/j.1742-4658.2012.08619.x.
36. Guan M, Fousek K, Jiang C, Guo S, Synold T, Xi B, Shih CC, Chow WA. 2011. Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6. Clin. Cancer Res. 17:1796-1806. http://dx.doi.org/10.1158/1078-0432.CCR-10-3216.
37. Jiang W, Mikochik PJ, Ra JH, Lei H, Flaherty KT, Winkler JD, Spitz FR. 2007. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res. 67:1221-1227. http://dx.doi.org/10.1158/0008-5472.CAN-06-3377.
38. Shim JS, Rao R, Beebe K, Neckers L, Han I, Nahta R, Liu JO. 2012. Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. J. Natl. Cancer Inst. 104:1576-1590. http://dx.doi.org/10.1093/jnci/djs396.
39. Caron M, Auclair M, Sterlingot H, Kornprobst M, Capeau J. 2003. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 17: 2437-2444. http://dx.doi.org/10.1097/00002030-200311210-00005.
40. Whealy ME, Card JP, Meade RP, Robbins AK, Enquist LW. 1991. Effect of brefeldin A on alphaherpesvirus membrane protein glycosylation and virus egress. J. Virol. 65:1066-1081.
41. Dennis PA, Blumenthal G, Ballas M, Gardner E, Kawabata S, LoPiccolo J, Helsabck C, Root H, Figg WD, Bernstein W. 2009. ASCO Annu. Meet., abstr 2853.
42. Pan J, Mott M, Xi B, Hepner E, Guan M, Fousek K, Magnusson R, Tinsley R, Valdes F, Frankel P, Synold T, Chow WA. 2012. Phase I study of nelfinavir in liposarcoma. Cancer Chemother. Pharmacol. 70:791-799. http://dx.doi.org/10.1007/s00280-012-1961-4.